Alnylam Reviews

7 Reviews
3.6
7 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Alnylam CEO and Director John M. Maraganore
John M. Maraganore
6 Ratings
  1.  

    GREAT WORK ENVIROMENT

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Intern in Cambridge, MA
    Former Employee - Intern in Cambridge, MA

    I worked at Alnylam full-time (less than an year)

    Pros

    learning opportunities, good culture, smaller company

    Cons

    Management, Lack of accountability

    Recommends
    Neutral Outlook
    Approves of CEO

Alnylam Interviews

Interview Experience

Interview Experience

100%
0%
0%

Getting an Interview

Getting an Interview

50%
50%

Interview Difficulty

2.5
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Senior Research Associate Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Application Details

    I applied through an employee referral. The process took 2 weeksinterviewed at Alnylam.

    Interview Details

    Hiring was fast and aggressive. I only had a weekend to review the offer and submit my answer. The interview did not require a presentation and met with colleagues on 2 different visits. Everyone was nice and the discussions focused on relevant information.

    Interview Questions
    Negotiation Details
    I was not able to get them to budge on start date or salary.
    Accepted Offer
    Positive Experience
    Easy Interview

Alnylam Awards & Accolades

Something missing? Add an award
Top Places to Work Globe 100, Boston Globe, 2008

Additional Info

Unlock Profile
Website www.alnylam.com
Headquarters Cambridge, MA
Size 150 to 499 Employees
Founded 2003
Type Company - Public (ALNY)
Industry Biotech & Pharmaceuticals
Revenue $25 to $50 million (USD) per year
Competitors Pfizer, Biovail

Call it The Silence of the Genes. Alnylam Pharmaceuticals runs interference with RNA to prevent disease. RNA interference (RNAi) technology developed by the biotech firm can selectively shut off harmful genes. The company is developing a pipeline of candidates both individually and through collaborations with other drugmakers. Its disease targets include rare genetic disorder ATTR (transthyretin-mediated amyloidosis) and RSV (respiratory syncytial virus), a common childhood viral infection. Additional R&D programs target neurological disorders, cardiovascular conditions... More

Work at Alnylam? Share Your Experiences

Alnylam

 
Click to Rate
or